Form 4: Cue Biopharma CEO Daniel Passeri Acquires 400,000 Stock Options
SEC Form 4 Filing
Cue Biopharma's CEO, Daniel Passeri, reports the acquisition of 400,000 stock options exercisable over time.
Summary
- Daniel R Passeri, CEO of Cue Biopharma, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction on March 6, 2024, where Passeri acquired 400,000 stock options.
- These options have an exercise price of $1.94.
- The options become exercisable in eight equal semi-annual installments starting September 6, 2024.
- The expiration date for these options is March 5, 2034.
- Following the reported transaction, Passeri directly owns 400,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are routine disclosures required by the SEC to ensure transparency in trading activities by company insiders. This filing indicates compensation for the CEO.
Stakeholder Impact
- The stock option grant could incentivize the CEO to improve company performance, potentially benefiting shareholders.
- The grant has a dilutive effect on existing shareholders, although the effect is likely to be small.
Key Dates
| Date | Description |
|---|---|
| 03/06/2024 | Date of stock option acquisition |
| 09/06/2024 | First vesting date for the stock options |
| 03/05/2034 | Expiration date of the stock options |
| 03/08/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.